berlex

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-2015
0246819842015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Purpose: Granulocyte/macrophage colony-stimulating factor (GM-CSF) administered locally together with vaccines can augment T-cell… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
OBJECTIVES Acute and chronic rejection remain unresolved problems after lung transplantation, despite heavy multidrug… (More)
  • table 1
  • figure 1
  • figure 3
Is this relevant?
2003
2003
BACKGROUND We combined alemtuzumab (Campath-1H, Berlex Laboratories, Montville, NJ) and tacrolimus (Tac) immunosuppression for… (More)
Is this relevant?
Review
2002
Review
2002
  • Uma Sinha
  • Current opinion in investigational drugs
  • 2002
Berlex (a Schering subsidiary) and Pfizer (formerly Parke-Davis) are developing ZK-807834 (CI-1031), one of a series of Factor Xa… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
'Transfection Agents (TA) mixed with FDA approved superparamagnetic iron oxide nanoparticle (SPIO), effectively coating the SPIO… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2002
Review
2002
Berlex and its parent company, Schering AG, are developing BX-471 (also known as ZK-811752), the lead in a series of non-peptide… (More)
Is this relevant?
2000
2000
Berlex Biosciences is investigating several series of Factor Xa inhibitors aimed at the prevention and treatment of thrombotic… (More)
Is this relevant?
1996
1996
 
Is this relevant?
1984
1984
Steady-state bioavailability of sustained-release quinidine gluconate tablets manufactured by two companies was compared in a… (More)
Is this relevant?